Trial Profile
Sorafenib Long Term Extension Program
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Benign tumours; Cancer; Carcinoma; Liver cancer; Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- Acronyms STEP
- Sponsors Bayer
- 15 Oct 2021 Status changed from active, no longer recruiting to completed.
- 14 Oct 2021 This trial has been completed in Germany (Global end date: 24 Sep 2021).
- 17 Aug 2021 Planned End Date changed from 30 Jul 2021 to 30 Sep 2021.